BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Lentigen Corporation And Wave Biotech, LLC Announce Formation Of Collaboration


1/25/2007 5:22:06 PM

BALTIMORE and SOMERSET, N.J., Jan. 25 /PRNewswire/ -- Lentigen Corporation and Wave Biotech, LLC announced today that they have entered into a collaboration under which Wave Biotech will provide process and equipment expertise for Lentigen's manufacturing platform based on its proprietary lentiviral vector technology.

The highly efficient gene delivery properties of lentiviral vectors significantly reduce the cost, time and risk involved in biologics manufacturing. Wave's key products feature disposable contact materials that eliminate cleaning and validation, thereby further reducing costs in operations and drastically reducing the time-to-market for biological products.

"This is one of the many partnerships that we are forging to develop our lentiviral vector platform. We're excited to have Wave Biotech as one of our partners," said Dr. Boro Dropulic, founder and CEO of Lentigen.

Daniella Kranjac, VP Sales & Marketing of Wave Biotech, LLC commented, "As the leader in disposable bioreactors and supporting instrumentation, the Wave Biotech product line offers Lentigen an ideal platform technology for their production and contract manufacturing needs."

About Lentiviral Vectors

Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. Previous viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors could achieve high, but not stable gene delivery into cells. Other vectors such as murine retroviral vectors can deliver genes stably, but not efficiently.

Gene delivery is accomplished by the binding and fusing of the LV pseudotyped envelope protein to the target cell membrane. The LV RNA containing the gene or gene silencing sequence is then incorporated into the cell via reverse transcription creating a DNA complex. This complex enters the nucleus incorporating into the chromosomal DNA creating a stable molecule. The gene sequence is integrated in the chromosome and is copied along with the DNA during ongoing cell division.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit www.lentigen.com.

About Wave Biotech

Wave Biotech is a research-based company that develops and manufactures innovative process equipment for the pharmaceutical and biotechnology industries. The company's focus is on developing disposable bioprocessing equipment. Key products, such as the Wave Bioreactor(R), WaveMixer(R), FlexMixer(R), and Sterile Tube Fuser, feature disposable contact materials that eliminate cleaning and validation, thereby reducing costs in operations ranging from cell culture, media preparation, and buffer dissolution and thawing process intermediates to patient specific cell therapy in hospitals. These unique, patented devices can be installed and commissioned rapidly, thereby drastically reducing the time-to-market for biological products. For additional information, visit: www.wavebiotech.com

Contacts: Lentigen Corporation Greg Feulner, VP Business Development 443-543-5318 greg.feulner@lentigen.com Media Contact: Gregory Tiberend Richard Lewis Communications, Inc. 212-827-0020 gtiberend@rlcinc.com Investor Contact: Tara Spiess TS Communications Group, LLC 914-921-5900 spiess@biotechirpr.com Wave Biotech, LLC Daniella Kranjac, VP Sales & Marketing +1 732 302 3100 dkranjac@wavebiotech.com Media Contact: Kathleen Mersinger Wave Biotech, LLC +1 732 302 3100 kmersinger@wavebiotech.com

Lentigen Corporation

CONTACT: Greg Feulner, VP Business Development of Lentigen Corporation,+1-443-543-5318, or greg.feulner@lentigen.com; or Gregory Tiberend ofRichard Lewis Communications, Inc., +1-212-827-0020, orgtiberend@rlcinc.com, for Lentigen Corporation; or Tara Spiess of TSCommunications Group, LLC, +1-914-921-5900, or spiess@biotechirpr.com, forLentigen Corporation; or Daniella Kranjac, VP Sales & Marketing,dkranjac@wavebiotech.com, or Kathleen Mersinger,kmersinger@wavebiotech.com, +1-732-302-3100, both of Wave Biotech, LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES